WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says
Get Alerts SRPT Hot Sheet
Rating Summary:
30 Buy, 9 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 43
Join SI Premium – FREE
Roth Capital analyst Debjit Chattopadhyay is taking exception to the bearish article published in the WSJ about Sarepta Therapeutic (NASDAQ: SRPT) which compared the company to its mature peer BioMarin (NASDAQ: BMRN) on a 2016 price/sales metric. The analyst said the article was "both juvenile and uninformed,"
"We are cognizant of the risk of recommending Sarepta shares heading into 2H15, but believe Sarepta is now significantly well positioned and has a better drug than BMRN, and do not expect an RTF," Chattopadhyay
The analyst notes that unlike BMRN, Sarepta has already initiated multiple confirmatory studies.
Further, he said it is highly unlikely that the FDA would have asked SRPT to proceed with the filing only to hand it an RTF in 60 days.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $26.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Upgrades Airbus SE (AIR:FP) (EADSY) to Outperform, 'positive shift in sentiment has room to run'
- dormakaba Holding AG (DOKA:SW) PT Raised to CHF485 at Stifel
- Citi Downgrades Shinko Electric Industries Co Ltd (6967:JP) (SHEGF) to Neutral ahead of tender offer
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!